Axogen (AXGN) vs Solana (HSDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Axogen (AXGN) has outperformed Solana (HSDT) over the past year, gaining 110.8% versus a loss of 86.8%. Over five years, AXGN leads with a +164.6% price change compared with -100.0% for HSDT. Axogen is the larger company by market cap ($2.12 billion vs $154.9 million), about 13.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | HSDT |
|---|---|---|
| Share price | $36.18 | $2.38 |
| Market cap | $2.12B | $154.95M |
| 1-day change | +0.39% | -6.30% |
| YTD return | +10.54% | -17.65% |
| 1-year return | +110.84% | -86.80% |
| 5-year return | +164.61% | -100.00% |
| P/E ratio (TTM) | — | 0.04 |
| Forward P/E | 52.59 | — |
| EPS (TTM) | $-0.67 | $53.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.91 | $16.81 |
| 52-week low | $15.27 | $1.19 |
| Distance from 52-week high | -31.62% | -85.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +48.76% | +47.06% |
| Average volume | 1.22M | 351.13K |
| Shares outstanding | 58.67M | 65.10M |
| Employees | 622 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 13.7 times larger than Solana by market value ($2.12B vs $154.95M).
- AXGN has outperformed HSDT by 197.6 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About Solana
HSDT stock →Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 21 employees
AXGN vs HSDT FAQ
Which is bigger, Axogen or Solana?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $154.95M for Solana (HSDT).
Which stock has performed better over the past year, AXGN or HSDT?
AXGN returned +110.84% over the past 12 months, compared with -86.80% for HSDT (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and Solana in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.